Non-Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Pharmacokinetics (PK) studies is the fastest growing sector, North America is the largest market

The Global Non-Clinical Trials Market is forecast to grow from USD 11.23 Billion in 2025 to USD 16.65 Billion by 2031, achieving a 6.78% CAGR, as these essential in vitro and in vivo studies evaluate drug candidate safety, toxicity, and efficacy before human trials. This market expansion is primarily driven by escalating global investment in drug discovery pipelines, prompted by the rising prevalence of chronic and complex diseases, with the European pharmaceutical industry alone investing approximately €55 billion in R&D in 2024. However, the market faces a significant challenge from ethical and regulatory pressures surrounding animal testing, compelling a shift towards alternative methods like computer modeling or organ-on-a-chip technologies; while ethically progressive, the complex validation processes and high costs of integrating these non-animal alternatives into regulatory frameworks can cause operational delays and impede immediate market growth.

Market Drivers

The primary catalyst for the Global Non-Clinical Trials Market is the substantial surge in pharmaceutical and biotechnology R&D expenditure, as increased investment directly translates to a higher volume of drug candidates requiring rigorous safety assessments, evidenced by AstraZeneca's 24% rise in R&D expenses to $13.6 billion and the FDA's approval of 50 novel drugs in 2024, each necessitating extensive prior non-clinical testing. A second major driver is the growing trend of outsourcing non-clinical studies to Contract Research Organizations (CROs), which allows companies to leverage specialized external expertise, optimize costs, and focus internal resources on core discovery efforts, maintaining substantial revenue for service providers like Charles River Laboratories, which reported $1.00 billion in revenue for Q3 2025, while also accelerating development timelines and providing access to advanced testing technologies.

Market Challenges

A significant hurdle for the Global Non-Clinical Trials Market is the stringent regulatory landscape, largely fueled by ethical concerns regarding animal welfare, which compels pharmaceutical companies to reduce their reliance on established in vivo testing models. This mandated transition creates a bottleneck due to the resource-intensive and prolonged validation processes for non-animal alternatives, disrupting workflows and leading to a contraction in traditional testing volumes that complicates safety data generation and slows overall drug development timelines. This tightening is evidenced by the UK Home Office's report of a decrease in scientific procedures involving living animals to approximately 2.64 million in Great Britain in 2024, marking the lowest level since 2001; however, the lack of universal regulatory acceptance and costly customization for alternative methodologies extend development timelines and increase operational expenditures, directly impeding efficient market scaling.

Market Trends

The Integration of Artificial Intelligence (AI) for predictive toxicology and safety assessment is fundamentally reshaping non-clinical workflows by enabling pharmaceutical companies to deploy machine learning algorithms for early identification of potential toxicity risks before physical testing, thus accelerating candidate selection and enhancing safety profile precision, exemplified by Sanofi's 2024 strategic partnership with Formation Bio and OpenAI to develop AI-powered software for drug development. Concurrently, the Expansion of Specialized Safety Testing for Biologics and Advanced Therapies is gaining momentum as the pipeline shifts towards complex cell and gene therapies requiring bespoke protocols for risks like immunogenicity and tumorigenicity, creating demand for highly specialized toxicology services. This trend is supported by substantial capital inflows, with the cell and gene therapy sector receiving $10.9 billion in investments in the first half of 2024, driven by late-stage clinical progress, ensuring funding for these rigorous non-clinical studies.

Key Market Players

• Thermo Fisher Scientific Inc.
• Charles River Laboratories International, Inc.
• Covance Inc.
• IQVIA Holdings, Inc.
• WuXi AppTec Co., Ltd.
• Eurofins Scientific
• Evotec SE
• Envigo RMS, LLC
• Absorption Systems, LLC

Report Scope

In this report, the Global Non-Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Clinical Trials Market, by Study Type:

• Pharmacodynamics (PD) studies
• Pharmacokinetics (PK) studies
• Toxicology studies

Non-Clinical Trials Market, by Test:

• In silico
• In vitro
• In vivo

Non-Clinical Trials Market, by Therapeutic Area:

• Oncology
• Cardiovascular
• Neurology
• Immunology
• Others

Non-Clinical Trials Market, by End User:

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic and Government Research Institutes
• Others

Non-Clinical Trials Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Clinical Trials Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.